Financial Review: LENZ Therapeutics (LENZ) and Its Competitors

LENZ Therapeutics (NASDAQ:LENZ) is one of 290 public companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its peers? We will compare LENZ Therapeutics to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk.

Valuation and Earnings

This table compares LENZ Therapeutics and its peers revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
LENZ Therapeutics	N/A	-$124.65 million	-1.05
LENZ Therapeutics Competitors	$535.68 million	-$37.27 million	8.95

LENZ Therapeutics’ peers have higher revenue and earnings than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

LENZ Therapeutics has a beta of 0.33, suggesting that its stock price is 67% less volatile than the S&P 500. Comparatively, LENZ Therapeutics’ peers have a beta of 1.09, suggesting that their average stock price is 9% more volatile than the S&P 500.

Insider and Institutional Ownership

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 50.2% of shares of all “Biological products, except diagnostic” companies are held by institutional investors. 38.4% of LENZ Therapeutics shares are held by company insiders. Comparatively, 16.2% of shares of all “Biological products, except diagnostic” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares LENZ Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	N/A	-33.12%	-27.96%
LENZ Therapeutics Competitors	-4,480.02%	-224.14%	-45.19%

Analyst Ratings

This is a summary of recent ratings and recommmendations for LENZ Therapeutics and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	0	0	5	0	3.00
LENZ Therapeutics Competitors	1437	4558	11931	208	2.60

LENZ Therapeutics presently has a consensus price target of $31.33, indicating a potential upside of 90.36%. As a group, “Biological products, except diagnostic” companies have a potential upside of 66.87%. Given LENZ Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than its peers.

Summary

LENZ Therapeutics beats its peers on 8 of the 13 factors compared.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.